Krishna Institute of Medical Sciences Ltd
Q2 FY23 Earnings Call Analysis
Healthcare Services
fundraise: Yescapex: Yesrevenue: Category 3margin: Category 3orderbook: No information
💰fundraise
Any current/future new fundraising through debt or equity?
- There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
- Finance cost has doubled this quarter mainly due to drawing down limits for Sunshine units.
- Management stated financing options include using existing limits for capex or drawing from available profits.
- No definitive commitment or plan for fresh debt or equity issuance was shared.
- Expansion projects are primarily funded by internal accruals or existing credit limits.
- The company appears focused on operational growth and capacity ramp-up rather than new external fundraising currently.
🏗️capex
Any current/future capex/capital investment/strategic investment?
- Capex will start mostly from next fiscal year, with significant investment planned for new hospitals and facility expansions.
- Bangalore: Two hospitals with 750 beds combined, INR 650 crores total outlay (~INR 80 lakhs per bed); one asset 50% owned, other on revenue share model.
- Thane project: INR 400 crores capex, with construction underway and transaction closure with investor expected soon; operational by Q1 or Q2 of next fiscal.
- Nashik hospital projected to be operational by Q4 of current financial year or early Q1 next year.
- Kondapur expansion: Incremental 400 beds planned to begin two years from now.
- Expansion in Andhra with new oncology centers and mother & child care units across multiple facilities.
- Emphasis on ramping up Sunshine and Nagpur hospitals, including shifting OPD/IPD in Sunshine from August.
- Corporate overhead costs currently impacting Telangana cluster margins due to expansion activities.
📊revenue
Future growth expectations in sales/revenue/volumes?
- Telangana and Andhra Pradesh clusters continue revenue growth at 15% YoY, with room for new specialty additions (oncology, mother & child care, interventional procedures) to drive further growth.
- Incremental bed additions of ~1500 beds in Andhra and Telangana over 24-36 months, maintaining occupancy around 70-75%.
- Sunshine and Nagpur hospitals expected to scale up with improved occupancy and doctor additions, contributing positively to revenue.
- New facilities in Bangalore (750 beds) to start operations between Q1 and Q2 FY25, with significant capex (~INR 650 crores).
- Thane and Nashik projects progressing with expected capacity additions.
- ARPOB (Average Revenue Per Occupied Bed) expected to grow at a blended 3-5% rate, driven mainly by new clinical therapies and pricing from insurance.
- EBITDA margins anticipated to improve as new facilities mature, with incremental revenue converting 40% directly to EBITDA in key clusters.
📈margin
Future growth expectations in earnings/operating earnings/profits/EPS?
- Incremental revenue growth driven by onboarding 25-30 new doctors leading to higher earnings.
- Telangana and Andhra Pradesh clusters expected to maintain and improve EBITDA margins; Telangana targets 30% margin in 24 months, Andhra Pradesh aims for 25%-27%.
- Sunshine and Nagpur facilities anticipated to improve margins and revenues as new hospitals scale up.
- New pediatric and mother-child specialty services expected to contribute to revenue growth without significant pricing hikes.
- Expansion in Bangalore (750 beds), Thane, and Nagpur to add capacity with expected gradual EBITDA margin stabilization.
- ARPOB growth expected around 3%-5% blended, driven mainly by case mix and new therapies rather than price increases.
- Corporate overheads and higher consumable costs currently suppress margins but expected to normalize with scale.
- Overall, incremental revenues in Telangana and Andhra are expected to yield approximately 40% EBITDA flow-through, supporting strong profit growth.
📋orderbook
Current/ Expected Orderbook/ Pending Orders?
The transcript does not explicitly mention details about the current or expected order book or pending orders related to KIMS Hospitals. The discussions primarily cover operational updates, expansion plans, bed additions, revenue growth, margins, price hikes, doctor specialties, and financial performance for Q1 FY24. There is no direct information provided regarding order book or pending orders for capital expenditure or other contracts. If you seek details on ongoing or future projects, the call highlights expansions in Bangalore, Thane, Nashik, Andhra Pradesh, Telangana, Sunshine Hospital ramp-up, and Nagpur hospital, which could imply ongoing investment and operational buildup, but no quantified order book or pending order data is shared.
